Equity · Healthcare
ACRS
NASDAQAclaris Therapeutics (ACRS)
The line runs 6.30 USD on 24 August through 3.45 USD on 20 November, on a scale from 3 to 7. Days the market did not trade hold the previous close, flat.
- Market cap
- 547.2M USD
- Revenue, year to Dec 2025
- 7.8M USD
- EPS, diluted, year to Dec 2025
- −0.53 USD
- 52-week range
- 2.33 USD – 6.54 USD
- Avg volume
- 212.8K
as of Nov 20, 2026
Have Aclaris Therapeutics (ACRS) insiders bought or sold shares recently?
ACRS's newest Form 4 filing is dated 1 August 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 23 Apr 2026 | Leonard Braden Michael10% Owner | Sell | 300,000 | 1.4M USD |
36 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Aug 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Option exercise | 36,375 | |
| 01 Aug 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Tax withheld | 12,385 | 64K USD |
| 05 Jun 2026 | SCHIFF ANDREW NDirector | Option exercise | 11,580 | |
| 05 Jun 2026 | MILANO VINCENTDirector | Option exercise | 11,580 | |
| 05 Jun 2026 | GOWEN MAXINEDirector | Option exercise | 11,580 | |
| 05 Jun 2026 | Mehra AnandDirector | Option exercise | 11,580 | |
| 05 Jun 2026 | Molineaux Christopher P.Director | Option exercise | 11,580 | |
| 05 Jun 2026 | Humphries William D.Director | Option exercise | 11,580 | |
| 01 May 2026 | Hall Jesse WayneChief Medical Officer | Option exercise | 36,375 | |
| 01 May 2026 | Hall Jesse WayneChief Medical Officer | Tax withheld | 9,330 | 41K USD |
| 01 Mar 2026 | Balthaser KevinChief Financial Officer | Option exercise | 2,375 | |
| 01 Mar 2026 | Balthaser KevinChief Financial Officer | Tax withheld | 677 | 2K USD |
Showing the 12 most recent of 36 compensation filings in this window. The figures above count all of them.
Which funds hold Aclaris Therapeutics (ACRS)?
7 of the 45 institutional funds we track reported a Aclaris Therapeutics position for the quarter ended 30 Sep 2026 — a combined 21.6M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Held (±25%) | 1,775,495 | 9.3M USD | +0.8% |
| Balyasny Asset Management | Trimmed | 1,410,299 | 7.4M USD | −30.3% |
| Marshall Wace | New position | 630,857 | 3.3M USD | |
| Two Sigma Investments | Trimmed | 98,668 | 519K USD | −25.9% |
| Renaissance Technologies | Trimmed | 82,812 | 436K USD | −89.9% |
| AQR Capital Management | Held (±25%) | 63,124 | 332K USD | +4.8% |
| Millennium Management | Trimmed | 50,673 | 267K USD | −90.3% |
| D. E. Shaw & Co. | Exited |
What has been filed or recorded for Aclaris Therapeutics (ACRS)?
The filings we hold for Aclaris Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,908 shares | 18K USD notional · 0.003% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,994 shares | 19K USD notional · 0.003% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 999 shares | 4K USD notional · 0.001% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 10 shares | 35 USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 706 shares | 3K USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,799,502 shares | 6.1M USD notional · 1.135% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.12 USD | |
| 30 Sep 2026 | Financials | Total assets | 216.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 166.8M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.15 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.15 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.53 USD | |
| 31 Dec 2025 | Financials | Revenue | 7.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −64.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.53 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.12 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.13 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.12 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.71 USD |
What do people ask about Aclaris Therapeutics (ACRS)?
What did Aclaris Therapeutics shares close at?3.45
Aclaris Therapeutics closed at 3.45 USD on 20 Nov 2026, down 1.43% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Aclaris Therapeutics’ market cap?547.2M
Aclaris Therapeutics is worth 547.2M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Aclaris Therapeutics’ revenue?7.8M
Aclaris Therapeutics reported revenue of 7.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Aclaris Therapeutics insiders bought or sold shares recently?
No Aclaris Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 1 Aug 2026 (SEC Form 4). See Insiders
Which funds own Aclaris Therapeutics?7 of 45
7 of the 45 funds we track reported a Aclaris Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Balyasny Asset Management and Marshall Wace. See Funds
When did Aclaris Therapeutics last report earnings?−0.12
Aclaris Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.12 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words